Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer: An initial interim safety report Meeting Abstract
| Authors: | Conlin, A. K.; Seidman, A. D.; Moynahan, M. E.; Traina, T.; Mace, J. R.; Meiri, E.; Bach, A.; Edwards, C.; Hudis, C. A. |
| Abstract Title: | Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer: An initial interim safety report |
| Meeting Title: | 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 25 |
| Issue: | 18 Suppl. |
| Meeting Dates: | 2007 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2007-06-20 |
| Start Page: | 58s |
| Language: | English |
| ACCESSION: | WOS:000455043700243 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2007.25.18_suppl.1104 |
| Notes: | Meeting Abstract: 1104 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
